文献速递真实世界研究与卫生经济流行病学与生物统计

肿瘤学成本效果分析中的赞助偏倚

Sponsorship bias in oncology cost effectiveness analysis.
PubMed 文献 · J Clin Epidemiol · 2023-02-10

该研究基于Tufts成本效果分析注册库1976至2021年的1537项肿瘤学成本效果分析,比较行业赞助与非行业赞助研究的特征与结论。结果显示25.2%由行业赞助,行业赞助研究更可能报告低于50000、100000和150000美元/QALY的增量成本效果比。作者认为肿瘤学成本效果分析存在显著赞助偏倚,可能影响药品定价与覆盖政策制定。

要点

  • 行业赞助的肿瘤学成本效果分析更可能报告低于50000美元/QALY的增量成本效果比(校正OR 1.91)。
  • 行业赞助研究也更可能报告低于100000美元/QALY(校正OR 2.74)和150000美元/QALY(校正OR 3.53)的增量成本效果比。
  • 作者认为肿瘤学成本效果分析存在显著赞助偏倚,可能对药品定价和覆盖政策制定产生深远影响。

核心结论

  • 作者认为肿瘤学成本效果分析中存在显著的赞助偏倚,该偏倚可能对药品定价和覆盖政策制定产生深远影响。

研究设计与样本

  • 分析Tufts成本效果分析注册库自1976年以来所有以增量成本每质量调整生命年(QALY)为健康效应的肿瘤学成本效果分析。
  • 共纳入1976至2021年发表的1537项肿瘤学成本效果分析,其中387项(25.2%)有行业赞助。
  • 采用描述性分析比较行业与非行业赞助成本效果分析的特征,并采用稳健logistic回归评估行业赞助与成本效果结论在多个阈值下的关系。

主要发现

  • 行业赞助的肿瘤学成本效果分析相比无行业赞助的研究,更可能报告低于50000美元/QALY的增量成本效果比(校正OR 1.91,95%CI 1.45-2.51,P<0.001)。
  • 行业赞助研究相比无行业赞助研究,更可能报告低于100000美元/QALY的增量成本效果比(校正OR 2.74,95%CI 1.98-3.79,P<0.001)。
  • 行业赞助研究相比无行业赞助研究,更可能报告低于150000美元/QALY的增量成本效果比(校正OR 3.53,95%CI 2.37-5.27,P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cost effectiveness analysis (CEA) has been increasingly used to inform cancer treatment coverage policy making worldwide. The primary objective of this study was to assess the association between industry sponsorship and CEA results in oncology. STUDY DESIGN AND SETTING: All CEAs in oncology used incremental cost per quality-adjusted life year (QALY) as health effect identified from the Tufts CEA Registry since 1976 was analyzed. Descriptive analyses were performed to present and compare the characteristics of CEA funded by industry and non-industry. Robust logistic regression was performed to assess the relationship between the industry sponsorship and cost effective conclusion over a wide range of threshold values. RESULTS: A total of 1537 CEAs in oncology published from 1976 to 2021 were included. There were 387 (25.2%) with the industry sponsorship. CEAs sponsored by the industry were more likely to report ICERs below $50,000/QALY (adjusted odds ratio (OR), 1.91, 95% confidence interval (CI), 1.45-2.51, P < 0.001), $100,000/QALY (2.74, 1.98-3.79, P < 0.001), and $150,000/QALY (3.53, 2.37-5.27, P < 0.001) than studies without industry sponsorship. CONCLUSIONS: Our study suggests that there has been a significant sponsorship bias in CEAs in oncology. This bias could have a profound implication on drug pricing and coverage policy making.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Zhou T, Xie F. Sponsorship bias in oncology cost effectiveness analysis. J Clin Epidemiol. 2023. PMID: 36773749. doi:10.1016/j.jclinepi.2023.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。